When does Hemgenix lose exclusivity?
Hemgenix (etranacogene dezaparvovec-dbyl) is a gene therapy for hemophilia B, and “losing exclusivity” usually refers to the end of patent and/or regulatory market exclusivity that keeps competitors from marketing the same product. The specific date depends on which exclusivity path you mean (patents versus FDA exclusivity), and the answer can also vary by country.
What kind of exclusivity could apply to Hemgenix?
In the U.S., exclusivity for biologics/gene therapies can come from multiple sources, most commonly:
- Composition or method patents held by the manufacturer.
- FDA marketing exclusivities tied to the approval pathway and regulatory data protections.
Because these run on different schedules, Hemgenix could “lose exclusivity” at different times depending on the legal basis being referenced.
Which country’s date matters?
The exclusivity end date is not universal. If you’re looking for the date that affects:
- U.S. generic/biosimilar entry prospects, you need the relevant U.S. patent(s)/FDA exclusivity.
- EU market protection, you need the relevant EU regulatory and patent status.
If you tell me the country (and whether you mean patent expiry or FDA exclusivity), I can narrow the answer to the specific trigger.
What’s the practical impact when exclusivity ends?
Once the relevant exclusivity ends, other companies can seek approval to market a competing product, subject to:
- Remaining patents that may still block commercial launch.
- Litigation (if a company challenges patent validity or infringement).
- Any regulatory requirements for demonstrating comparability/similarity (for biosimilar-type approaches).
Next question to pinpoint the exact date
Do you mean U.S. patent expiry, FDA exclusivity, or the first realistic time a competitor could launch? If you share the country (U.S. vs EU vs other) and which definition you’re using, I can give the precise “loses exclusivity” timing.